Physician profile
Glenn E Macnichol
NPI 1245297811
$4,105.07
in general payments reported to CMS, 2019-2025
32 companies · $521 in 2025
The $521 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $537 · 2021: $608 · 2022: $657 · 2023: $642 · 2024: $532 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,475.39 | 2019-2025 | Proclaim, Eterna, Octrode |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.59 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $389.08 | 2019-2025 | Belbuca |
| Ibsa Pharma INC. | $332.59 | 2022-2024 | Tirosint, Licart, Tirosint |
| Scilex Pharmaceuticals INC. | $192.85 | 2019-2023 | Ztlido |
| Nevro Corp. | $157.19 | 2020-2024 | Senza |
| Radius Health, INC. | $133.74 | 2019-2025 | Tymlos |
| Pfizer INC. | $132.72 | 2019-2025 | |
| Globus Medical, INC. | $81.40 | 2025 | Senza |
| Masimo Corporation | $70.70 | 2022 | |
| Arbor Pharmaceuticals, INC. | $69.80 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $48.41 | 2019-2020 | |
| Redhill Biopharma INC. | $46.82 | 2021 | |
| Smith+Nephew, INC. | $43.46 | 2020-2023 | Collagenase Santyl, Regranex |
| Vertex Pharmaceuticals Incorporated | $41.78 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $40.89 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $37.19 | 2023 | Levorphanol Tartrate |
| Organogenesis INC. | $36.29 | 2023 | Puraply |
| Horizon Therapeutics Plc | $33.75 | 2020 | |
| Abbvie INC. | $32.36 | 2022 | |
| Bioventus LLC | $30.21 | 2019-2025 | Xcell |
| Kci USA, INC. | $29.27 | 2020 | |
| Zimmer Biomet Holdings, INC. | $28.50 | 2019-2021 | |
| Mdd US Operations, LLC | $28.48 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $23.99 | 2022 | |
| Lilly USA, LLC | $22.49 | 2021 | |
| Integra Lifesciences Corporation | $19.29 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Pacira Pharmaceuticals Incorporated | $18.63 | 2024 | Exparel, Zilretta, Iovera |
| Valinor Pharma, LLC | $18.61 | 2024 | Movantik |
| Avanos Medical | $14.83 | 2021 | |
| Daiichi Sankyo INC. | $14.67 | 2019 | |
| Boston Scientific Corporation | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Macnichol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.